Effect of tofacitinib in COVID-19

Phase 2

Recruiting

Conditions: Condition 1: COVID-19. Condition 2: COVID-19.
virus identified
virus not identified
Clinically-epidemiologically diagnosed COVID-19
Probable COVID-19
Suspected COVID-19
U07.1
U07.2

Registration Number: IRCT20200329046892N2

Lead Sponsor: Rasht University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

All patients with severe Covid-19 admitted to the ICU of Razi Hospital in Rasht for period of March- June 2021
Age greater than or equal to 18 years
Patients admitted with the following criteria: fever (oral temperature greater than 37.2 ° C), dry cough, severe tiredness or dyspnea
At least one of the following criteria : positive PCR OR lung involvement on chest X-ray / CT scan
Absolute lymphocyte count greater than or equal to 200 per cubic millimeter
Absolute neutrophil count greater than or equal to 1000 per milliliter Cubic meters
Hemoglobin above 8 grams per deciliter

Exclusion Criteria

Lack of informed consent
Lack of patient cooperation
Having pulmonary embolism or intravascular thrombosis
Having another active infection
Having diverticulitis and gastric ulcer
Having tuberculosis or hepatitis B or active hepatitis C or HIV
Any major drug interaction between routine patient's drugs with any of the study drugs
Pregnancy and lactation
Simultaneous presence in other research study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The time required to improve clinical symptoms and within 14 days of treatment start. Timepoint: Daily from the first day of intervention. Method of measurement: Physical examination.

Secondary Outcome Measures